urea has been researched along with Crohn Disease in 10 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Crohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In several cases with IgA nephropathy (IgAN), differential diagnosis is difficult due to the complication with other systemic diseases which can induce secondary IgAN." | 1.62 | Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. ( Fukao, Y; Kano, T; Kato, R; Lee, M; Makita, Y; Nakayama, M; Suzuki, H; Suzuki, Y, 2021) |
| " Information on bioavailability and release characteristics of ColoPulse tablets in Crohn's patients and the influence of food and time of food intake is a prerequisite to properly design future clinical studies with active substances in these patients." | 1.39 | ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. ( Buurman, DJ; Dijkstra, G; Frijlink, HW; Kosterink, JG; Maurer, JM; Schellekens, RC; Stellaard, F; van Rieke, HM; Woerdenbag, HJ; Wutzke, KD, 2013) |
| "Children with Crohn disease have altered growth and body composition." | 1.37 | Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease. ( Denne, SC; Noe, JD; Steiner, SJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, M | 1 |
| Suzuki, H | 1 |
| Kato, R | 1 |
| Fukao, Y | 1 |
| Nakayama, M | 1 |
| Kano, T | 1 |
| Makita, Y | 1 |
| Suzuki, Y | 1 |
| Maurer, JM | 1 |
| Schellekens, RC | 1 |
| van Rieke, HM | 1 |
| Stellaard, F | 1 |
| Wutzke, KD | 1 |
| Buurman, DJ | 1 |
| Dijkstra, G | 1 |
| Woerdenbag, HJ | 1 |
| Frijlink, HW | 1 |
| Kosterink, JG | 1 |
| Ando, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Maeda, O | 1 |
| Ishikawa, D | 1 |
| Minami, M | 1 |
| Hasegawa, M | 1 |
| Kondo, S | 1 |
| Goto, Y | 1 |
| Ohmiya, N | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Steiner, SJ | 1 |
| Noe, JD | 1 |
| Denne, SC | 1 |
| RUBINIETZ, H | 1 |
| Kasper, H | 1 |
| Sommer, H | 1 |
| Lundsgaard, C | 2 |
| Hamberg, O | 2 |
| Thomsen, OO | 2 |
| Nielsen, OH | 2 |
| Vilstrup, H | 2 |
| Rask-Madsen, J | 1 |
| Hammersgaard, EA | 1 |
| Knudsen, E | 1 |
| Wochner, RD | 1 |
| Weissman, SM | 1 |
| Waldmann, TA | 1 |
| Houston, D | 1 |
| Berlin, NI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery[NCT02716285] | Phase 3 | 190 participants (Actual) | Interventional | 2016-08-17 | Completed | ||
| A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Heal[NCT02291445] | Phase 2 | 8 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the plasma concentration-time curve from t=0 hrs until t=24 hrs. (NCT02291445)
Timeframe: 24 hours
| Intervention | ug*h/L (Median) |
|---|---|
| Ileocolonic Release PO | 2331 |
| Small Intestinal Release PO | 2623 |
Menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) peak plasma concentrations (NCT02291445)
Timeframe: 24 hours
| Intervention | ug/L (Median) |
|---|---|
| Ileocolonic Release PO | 563.6 |
| Small Intestinal Release PO | 702 |
Time until a measurable plasma concentration of menthol-glucuronide occurs after oral administration of peppermint oil (45ug/L) (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 225 |
| Small Intestinal Release PO | 37 |
Time to reach maximum menthol-glucuronide (main constituent of peppermint oil after conversion by the liver) concentration in plasma (NCT02291445)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ileocolonic Release PO | 360 |
| Small Intestinal Release PO | 180 |
elimination half-life; time required for the plasma concentration of menthol-glucuronide to reach half of its original value. (NCT02291445)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Ileocolonic Release PO | 6.1 |
| Small Intestinal Release PO | 7.7 |
1 trial available for urea and Crohn Disease
| Article | Year |
|---|---|
Increased hepatic urea synthesis in patients with active inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Amino Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Linear Mod | 1996 |
9 other studies available for urea and Crohn Disease
| Article | Year |
|---|---|
Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; Crohn Disease; Diagnosis, Di | 2021 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Colon; Crohn Disease; Cross-Over S | 2013 |
Relationships between Helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of Crohn's disease patients.
Topics: Adolescent; Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biopsy; Breath Tests; Ca | 2008 |
Corticosteroids increase protein breakdown and loss in newly diagnosed pediatric Crohn disease.
Topics: Adolescent; Blood Glucose; Body Composition; Child; Crohn Disease; Gas Chromatography-Mass Spectrome | 2011 |
[Ileitis terminalis; treatment with intestin-euvernil].
Topics: Crohn Disease; Humans; Ileitis; Urea | 1955 |
Taste thresholds in patients with Crohn's disease.
Topics: Adolescent; Adult; Aged; Crohn Disease; Female; Humans; Hydrochloric Acid; Male; Middle Aged; Nutrit | 1980 |
[Increased urea synthesis in patients with active inflammatory bowel disease].
Topics: Adult; Amino Acids; Blood Urea Nitrogen; Colitis, Ulcerative; Crohn Disease; Female; Humans; Interle | 1997 |
Rectal electrolyte transport and mucosal permeability in ulcerative colitis and Crohn's disease.
Topics: Adult; Bicarbonates; Biological Transport, Active; Chromium Isotopes; Colitis, Ulcerative; Crohn Dis | 1973 |
Direct measurement of the rates of synthesis of plasma proteins in control subjects and patients with gastrointestinal protein loss.
Topics: Amyotrophic Lateral Sclerosis; Arginine; Bicarbonates; Blood Proteins; Carbon Isotopes; Crohn Diseas | 1968 |